NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the Phase 1 dose-expansion cohort is ongoing - Milestone payment earned from Merck for initiation of IND-enabling study and from EMD...
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 9, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein...
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., July 29, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Nicki Vasquez, SVP Alliance Management/Portfolio Strategy and Operations Interviewed by Elaine Quilici of Pharmaceutical Executive – “Firsthand Views: Latinos in Pharma”
Pharmaceutical Executive Firsthand Views: Latinos in Pharma https://www.pharmexec.com/view/firsthand-views-latinos-in-pharma July 8, 2021 Elaine Quilici Latino executives share their experiences and insights on the community’s contributions to the life sciences...
Bill Newell, CEO Interviewed by Peter Hofland of The Onco’Zine Brief – “Antibody-Drug Conjugates: Coming of Age”
In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors...
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June
SOUTH SAN FRANCISCO, Calif., June 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Poster
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian Cancer Download Poster, CLICK HERE
American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation
Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial Ovarian CancerDownload Presentation, CLICK HERE
Jefferies Virtual Healthcare Conference 2021 – Presentation
Webcast, Jun 2, 2021 at 4:30pm EST Download Presentation, Click Here
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
SOUTH SAN FRANCISCO, Calif., June 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
